See more : Hess Corporation (AHC.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Seres Therapeutics, Inc. (MCRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Seres Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shenzhen Changfang Group Co., Ltd. (300301.SZ) Income Statement Analysis – Financial Results
- Canadian Tire Corporation, Limited (CDNTF) Income Statement Analysis – Financial Results
- Kintavar Exploration Inc. (KTR.V) Income Statement Analysis – Financial Results
- BlackRock Income Trust, Inc. (BKT) Income Statement Analysis – Financial Results
- Aesthetic Medical International Holdings Group Limited (PAIYY) Income Statement Analysis – Financial Results
Seres Therapeutics, Inc. (MCRB)
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 126.33M | 7.13M | 144.93M | 33.22M | 34.51M | 28.27M | 32.10M | 21.77M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 704.00K | 1.00M | 1.73M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 728.00K | 10.72M | 0.00 | 0.00 |
| Gross Profit | 125.62M | 6.12M | 143.20M | -57.36M | -45.64M | -67.69M | -57.36M | -60.22M | -728.00K | -10.72M | 0.00 | 0.00 |
| Gross Profit Ratio | 99.44% | 85.91% | 98.80% | -172.68% | -132.26% | -239.46% | -178.68% | -276.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.86M | 172.92M | 141.89M | 90.57M | 80.14M | 95.96M | 89.46M | 81.99M | 38.10M | 10.72M | 4.81M | 2.08M |
| General & Administrative | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 87.74M | 79.69M | 69.26M | 30.78M | 24.75M | 32.60M | 34.04M | 32.62M | 16.76M | 4.36M | 1.25M | 956.00K |
| Other Expenses | 0.00 | 1.00M | -1.73M | 981.00K | 1.07M | 170.00K | 425.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 233.60M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Cost & Expenses | 234.31M | 253.62M | 209.42M | 121.35M | 104.89M | 128.55M | 123.50M | 114.61M | 54.86M | 15.08M | 6.05M | 3.03M |
| Interest Income | 7.30M | 3.06M | 2.87M | 946.00K | 1.03M | 0.00 | 0.00 | 2.23M | 638.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.18M | 6.02M | 2.91M | 2.92M | 502.00K | 1.17M | 1.59M | 969.00K | 555.00K | 0.00 | 42.00K | 0.00 |
| Depreciation & Amortization | 6.24M | 11.85M | 9.22M | 8.89M | 9.83M | 7.86M | 7.26M | 4.21M | 728.00K | 190.00K | 88.00K | 25.00K |
| EBITDA | -94.31M | -237.51M | -56.72M | -77.31M | -59.95M | -91.08M | -82.12M | -88.63M | -54.13M | -14.89M | -5.96M | -3.01M |
| EBITDA Ratio | -74.65% | -3,425.04% | -43.24% | -259.53% | -197.90% | -354.77% | -262.11% | -396.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -107.98M | -246.49M | -64.49M | -88.13M | -71.88M | -100.28M | -91.40M | -92.84M | -54.86M | -15.08M | -6.05M | -3.03M |
| Operating Income Ratio | -85.48% | -3,458.05% | -44.50% | -265.33% | -208.31% | -354.77% | -284.72% | -426.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.74M | -3.67M | -1.09M | -997.00K | 1.60M | 1.34M | 2.02M | 1.26M | 76.00K | -1.63M | -50.00K | -93.00K |
| Income Before Tax | -113.72M | -250.16M | -65.58M | -89.13M | -70.28M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Income Before Tax Ratio | -90.02% | -3,509.50% | -45.25% | -268.33% | -203.68% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.67M | -4.08M | -2.67M | -6.04M | 1.34M | -1.59M | 2.23M | -804.00K | 1.63M | 42.00K | 0.00 |
| Net Income | -113.72M | -253.82M | -61.50M | -86.45M | -64.24M | -98.94M | -89.38M | -91.58M | -54.78M | -16.71M | -6.10M | -3.13M |
| Net Income Ratio | -90.02% | -3,560.94% | -42.43% | -260.29% | -186.19% | -350.03% | -278.44% | -420.74% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| EPS Diluted | -0.89 | -2.35 | -0.67 | -1.08 | -1.13 | -2.43 | -2.21 | -2.30 | -2.33 | -0.56 | -0.20 | -0.15 |
| Weighted Avg Shares Out | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
| Weighted Avg Shares Out (Dil) | 128.00M | 108.08M | 91.70M | 79.79M | 56.65M | 40.74M | 40.45M | 39.85M | 23.53M | 29.78M | 29.78M | 20.68M |
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate...
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced preliminary key VOWST (fecal microbiota spores, live-brpk) launch metrics and receipt of US FDA Fast Track Designation for SER-155 ahead of its presentation at the 42nd...
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 12:45 p.m. ET...
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) will be presented...
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET. An audio webcast of...
Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET Company Participants Kevin Mannix - Head, IR Eric Shaff - CEO Dr. Terri Young - Chief Commercial Officer David Arkowitz - CFO Conference Call...
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported financial results for the third quarter ended September 30, 2023, including VOWST net sales of $7.6 million. Third quarter VOWST commercial results show strong continued progress,...
Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results...
Seres Therapeutics to Highlight VOWST™ Data at IDWeek
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced multiple abstracts to be presented at IDWeek 2023 in Boston, Massachusetts (October 11-15, 2023), including two posters of post-hoc analyses from the ECOSPOR III and ECOSPOR IV Phase 3 trials, which...
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on October 4, 2023, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an aggregate...
Source: https://incomestatements.info
Category: Stock Reports